Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Neurosci Lett ; 810: 137332, 2023 07 27.
Article in English | MEDLINE | ID: mdl-37302565

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disease, often characterized by progressive deficits in memory and cognitive functions. Cholinesterase inhibitors have been introduced as promising agents to enhance cognition and memory in both human patients and animal models of AD. In the current study, we assessed the effects of a synthetic phenoxyethyl piperidine derivative, compound 7c, as a novel dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), on learning and memory, as well as serum and hippocampal AChE levels in an animal model of AD. The model of dementia was induced by intracerebroventricular injection of streptozotocin (STZ, 2 mg/kg) to male Wistar rats. STZ-treated rats received compound 7c (3, 30, and 300 µg/kg) for five consecutive days. ​Passive avoidance (PA) learning and memory, as well as spatial learning and memory using Morris water maze, were evaluated. The level of AChE was measured in the serum and the left and right hippocampus. Findings demonstrated that compound 7c (300 µg/kg) was able to reverse STZ-induced impairments in PA memory, while also reduced the increased AChE level in the left hippocampus. Taken together, compound 7c appeared to act as a central AChE inhibitor, and its role in alleviating cognitive deficits in the AD animal model suggests that it may have therapeutic potential in AD dementia. Further research is required to assess the effectiveness of compound 7c in more reliable models of AD in light of these preliminary findings.


Subject(s)
Alzheimer Disease , Neurodegenerative Diseases , Rats , Humans , Male , Animals , Streptozocin , Butyrylcholinesterase/adverse effects , Acetylcholinesterase , Rats, Wistar , Neurodegenerative Diseases/drug therapy , Memory Disorders/chemically induced , Maze Learning , Alzheimer Disease/chemically induced , Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/therapeutic use , Piperidines/pharmacology , Piperidines/therapeutic use , Disease Models, Animal
2.
Biomed Pharmacother ; 146: 112556, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34953393

ABSTRACT

Acetylcholinesterase (AChE) inhibitor is the first choice for the treatment of Alzheimer's disease (AD), but it has some defects, such as dose limitation and unsatisfactory long-term treatment effect. Recent studies have shown that butyrylcholinesterase (BuChE) inhibitors or double acetyl and butyryl cholinesterase inhibitors have better curative effects on AD, and the side effects are lower than those of specific AChE inhibitors. Dual target cholinesterase inhibitors have become a new hotspot in the research of anti-AD drugs. Herein, the synthesis and bioactivities of BuChE inhibitors were reviewed.


Subject(s)
Butyrylcholinesterase/pharmacology , Cholinesterase Inhibitors/pharmacology , Acridines/chemistry , Acridines/pharmacology , Alzheimer Disease/drug therapy , Butyrylcholinesterase/adverse effects , Butyrylcholinesterase/chemistry , Cholinesterase Inhibitors/adverse effects , Cholinesterase Inhibitors/chemistry , Humans , Methoxsalen/analogs & derivatives , Methoxsalen/chemistry , Methoxsalen/pharmacology , Structure-Activity Relationship
3.
Braz. J. Pharm. Sci. (Online) ; 58: e20464, 2022. tab, graf
Article in English | LILACS | ID: biblio-1403751

ABSTRACT

Abstract Papaveraceae is one of the prominent alkaloid-containing families, and plants of the genus Glaucium (Papaveraceae) are known for their bioactive alkaloids. Glaucium species have been used in traditional medicine in Turkey as an analgesic, narcotic, sedative, and antitussive. In this study, it was planned to evaluate the inhibitory activity of an alkaloidal extract of Glaucium corniculatum subsp. refractum on acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and prolyl oligopeptidase (POP), as well as exploring the chemical profile of the plant by using Gas Chromatography-Mass Spectrometry (GC-MS). The AChE, BuChE and POP inhibition activities of the alkaloidal extract of G. corniculatum subsp. refractum were determined spectrophotometrically. A rapid GC-MS method was used to identify alkaloids that could be responsible for these inhibition activities. In total, eleven alkaloids were identified in the alkaloid extract of the plant by GC-MS. Allocyptopine (52.92%) and protopine (25.38%) were found as the major constituents. The alkaloidal extract of G. corniculatum subsp. refractum showed potent AChE inhibitory activity (IC50:1.25 µg/mL) and BuChE inhibitory activity (IC50: 7.02 µg/mL). The extract also showed a remarkable inhibitory effect on POP with an IC50 value of 123.69 µg/mL. This study presents the first GC-MS investigation and POP inhibitory activity of G. corniculatum subsp. refractum.


Subject(s)
Acetylcholinesterase/adverse effects , Butyrylcholinesterase/adverse effects , Papaveraceae/metabolism , Plant Extracts/agonists , Alkaloids/analysis , Gas Chromatography-Mass Spectrometry/methods , Medicine, Traditional
4.
Braz. J. Pharm. Sci. (Online) ; 57: e18310, 2021. tab, graf
Article in English | LILACS | ID: biblio-1350230

ABSTRACT

This study aimed to evaluate the anticholinesterase activities of extracts and fractions of Ocotea daphnifolia in vitro and characterize its constituents. The effects of hexane, ethyl acetate, and ethanolic extracts on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activity were determined with a spectrophotometry assay. All extracts inhibited cholinesterase activity, and the ethanolic extract (2 mg/mL) exhibited the highest inhibition of both enzymes (99.7% for BuChE and 82.4% for AChE). The ethanolic extract was fractionated by column chromatography resulting in 14 fractions that were also screened for their anticholinesterase effects. Fraction 9 (2 mg/mL) showed the highest activity, inhibiting AChE and BuChE by 71.8% and 90.2%, respectively. This fraction was analyzed by high-performance liquid chromatography high-resolution mass spectrometry which allowed the characterization of seven glycosylated flavonoids (containing kaempferol and quercetin nucleus) and one alkaloid (reticuline). In order to better understand the enzyme-inhibitor interaction of the reticuline toward cholinesterase, molecular modeling studies were performed. Reticuline targeted the catalytic activity site of the enzymes. Ocotea daphnifolia exhibits a dual cholinesterase inhibitory activity and displays the same pattern of intermolecular interactions as described in the literature. The alkaloid reticuline can be considered as an important bioactive constituent of this plant.


Subject(s)
In Vitro Techniques/instrumentation , Cholinesterase Inhibitors/analysis , Lauraceae/classification , Ocotea/adverse effects , Molecular Docking Simulation/instrumentation , Plants, Medicinal/anatomy & histology , Acetylcholinesterase/adverse effects , Spectrophotometry/instrumentation , Flavonoids , Butyrylcholinesterase/adverse effects , Alkaloids
5.
J Med Chem ; 62(20): 9116-9140, 2019 10 24.
Article in English | MEDLINE | ID: mdl-31609115

ABSTRACT

In this study, the carbamate structure of pseudo-irreversible butyrylcholinesterase (BChE) inhibitors was optimized with regard to a longer binding to the enzyme. A set of compounds bearing different heterocycles (e.g., morpholine, tetrahydroisoquinoline, benzimidazole, piperidine) and alkylene spacers (2 to 10 methylene groups between carbamate and heterocycle) in the carbamate residue was synthesized and characterized in vitro for their binding affinity, binding kinetics, and carbamate hydrolysis. These novel BChE inhibitors are highly selective for hBChE over human acetycholinesterase (hAChE), yielding short-, medium-, and long-acting nanomolar hBChE inhibitors (with a half-life of the carbamoylated enzyme ranging from 1 to 28 h). The inhibitors show neuroprotective properties in a murine hippocampal cell line and a pharmacological mouse model of Alzheimer's disease (AD), suggesting a significant benefit of BChE inhibition for a disease-modifying treatment of AD.


Subject(s)
Alzheimer Disease/prevention & control , Butyrylcholinesterase/adverse effects , Carbamates/chemistry , Cholinesterase Inhibitors/pharmacology , Neuroprotective Agents/pharmacology , Animals , Cholinesterase Inhibitors/chemistry , Disease Models, Animal , Mice , Neuroprotective Agents/chemistry
6.
Drug Alcohol Depend ; 188: 295-303, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29807217

ABSTRACT

BACKGROUND: TV-1380 is a rationally mutated, human BChE fused to human serum albumin that has high hydrolytic enzymatic activity against cocaine and as well as an extended elimination half-life. OBJECTIVE: The present studies examined the safety of TV-1380 and its protective effect when given to monkeys alone or concomitantly with cocaine and ethanol. METHODS: A set of studies was conducted in monkeys with TV-1380. The parameters tested included telemetric assessment of cardiovascular parameters, clinical pathology, plasma analysis of cardiac troponin I, ex-vivo analyses of cocaethylene and PK analysis of serum concentrations of TV-1380, cocaine and its metabolites, and histopathological examinations. RESULTS: TV-1380 treatment in monkeys was well tolerated. TV-1380 pretreatment prior to cocaine significantly attenuated the cardiac effects of cocaine and reduced cocaine-induced elevations in serum cardiac troponin I. TV-1380 changed the metabolic fate of cocaine resulting in decreased exposure to benzoylecgonine, while increasing the exposure to ecgonine methyl ester in plasma.TV-1380 reduced the plasma levels of the toxic metabolite cocaethylene formed after co-administration of ethanol and cocaine. CONCLUSION: The results of this study demonstrate that TV-1380 not only accelerates the elimination of cocaine, but also protects the treated animal from the cardiac effects of cocaine, and inhibits the formation of the toxic cocaethylene metabolite when cocaine is given together with ethanol, supporting further clinical development of modified BChE products as possible treatments for cocaine abuse.


Subject(s)
Albumins/adverse effects , Albumins/pharmacology , Albumins/pharmacokinetics , Butyrylcholinesterase/adverse effects , Butyrylcholinesterase/pharmacology , Butyrylcholinesterase/pharmacokinetics , Cocaine/analogs & derivatives , Cocaine/antagonists & inhibitors , Ethanol/antagonists & inhibitors , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/pharmacokinetics , Animals , Butyrylcholinesterase/blood , Cocaine/blood , Cocaine/metabolism , Cocaine/pharmacokinetics , Cocaine/pharmacology , Drug Interactions , Electrocardiography/drug effects , Ethanol/blood , Ethanol/pharmacokinetics , Ethanol/pharmacology , Female , Heart Rate/drug effects , Humans , Macaca fascicularis , Male , Recombinant Fusion Proteins/blood , Respiration/drug effects , Troponin I/blood
7.
J Clin Pharmacol ; 55(5): 573-83, 2015 May.
Article in English | MEDLINE | ID: mdl-25524052

ABSTRACT

Human plasma butyrylcholinesterase (BChE) contributes to cocaine metabolism and has been considered for use in treating cocaine addiction and cocaine overdose. TV-1380 is a recombinant protein composed of the mature form of human serum albumin fused at its amino terminus to the carboxy-terminus of a truncated and mutated BChE. In preclinical studies, TV-1380 has been shown to rapidly eliminate cocaine in the plasma thus forestalling entry of cocaine into the brain and heart. Two randomized, blinded phase I studies were conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of TV-1380, following single and multiple administration in healthy subjects. TV-1380 was found to be safe and well tolerated with a long half-life (43-77 hours) and showed a dose-proportional increase in systemic exposure. Consistent with preclinical results, the ex vivo cocaine hydrolysis, TV-1380 activity clearly increased upon treatment in a dose-dependent manner. In addition, there was a direct relationship between ex vivo cocaine hydrolysis (kel ) and TV-1380 serum concentrations. There was no evidence that TV-1380 affected heart rate, the uncorrected QT interval, or the heart-rate-corrected QTcF interval. TV-1380, therefore, offers a safe once-weekly therapy to increase cocaine hydrolysis.


Subject(s)
Albumins/adverse effects , Albumins/pharmacology , Butyrylcholinesterase/adverse effects , Butyrylcholinesterase/pharmacology , Cocaine-Related Disorders/drug therapy , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/pharmacology , Adult , Albumins/pharmacokinetics , Area Under Curve , Butyrylcholinesterase/pharmacokinetics , Cocaine/metabolism , Dose-Response Relationship, Drug , Double-Blind Method , Electrocardiography , Female , Half-Life , Humans , Injections, Intramuscular , Male , Maximum Tolerated Dose , Metabolic Clearance Rate , Recombinant Fusion Proteins/pharmacokinetics , Recombinant Proteins
8.
Neurotoxicol Teratol ; 34(3): 323-30, 2012.
Article in English | MEDLINE | ID: mdl-22402122

ABSTRACT

The effects of a large dose of human serum butyrylcholinesterase (HuBChE) were evaluated in rhesus monkeys using a serial-probe recognition (SPR) task designed to assess attention and short-term memory. Each monkey received an intravenous injection of 150 mg (105,000 U or 30 mg/kg) of HuBChE 60 min prior to testing on the SPR task. Concurrent with the cognitive-behavioral assessment, blood was collected at various time points throughout the study and was analyzed for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities, anti-BChE antibody production and gross clinical pathology (i.e., complete blood count and clinical chemistry panel). HuBChE revealed a peak blood activity of 227 U/ml at 5 min after intravenous injection and a mean residence time of approximately 72 h. No cognitive-behavioral decrements of any kind in SPR performance and no toxic signs in clinical pathology were detected in any of the blood assays during the 5 weeks of observation. Anti-HuBChE antibodies peaked at about 14 days after injection, with no concomitant behavioral changes. These results demonstrate the behavioral and physiological safety of HuBChE in rhesus monkeys and support its development as a bioscavenger for the prophylaxis of chemical warfare agent toxicity in humans.


Subject(s)
Behavior, Animal , Butyrylcholinesterase/blood , Animals , Antidotes/adverse effects , Behavior, Animal/drug effects , Behavior, Animal/physiology , Blood Cell Count , Butyrylcholinesterase/adverse effects , Butyrylcholinesterase/immunology , Female , Humans , Immunoglobulin G/blood , Injections, Intravenous , Kidney Function Tests , Liver Function Tests , Macaca mulatta
9.
J Med Chem ; 54(8): 2627-45, 2011 Apr 28.
Article in English | MEDLINE | ID: mdl-21417225

ABSTRACT

A molecular library of quaternary ammonium salts (QASs), mainly composed of symmetrical bis-quaternary heterocyclic bromides exhibiting choline kinase (ChoK) inhibitory activity, were evaluated for their ability to inhibit acetyl- and butyrylcholinesterase (AChE and BChE, respectively). The molecular framework of QASs consisted of two positively charged heteroaromatic (pyridinium or quinolinium) or sterically hindered aliphatic (quinuclidinium) nitrogen rings kept at an appropriate distance by lipophilic rigid or semirigid linkers. Many homodimeric QASs showed AChE and BChE inhibitory potency in the nanomolar range along with a low enzymatic selectivity. Computational studies on AChE, BChE, and ChoK allowed identification of the key molecular determinants for high affinity and selectivity over either one of the three enzymes and guided the design of a hybrid bis-QAS (56) exhibiting the highest AChE affinity (IC(50) = 15 nM) and selectivity over BChE and ChoK (SI = 50 and 562, respectively) and a promising pharmacological potential in myasthenia gravis and neuromuscular blockade.


Subject(s)
Acetylcholinesterase/adverse effects , Butyrylcholinesterase/adverse effects , Cholinesterase Inhibitors/pharmacology , Heterocyclic Compounds/pharmacology , Quaternary Ammonium Compounds/pharmacology , Cations , Cholinesterase Inhibitors/chemistry , Dimerization , Heterocyclic Compounds/chemistry , Models, Molecular , Quaternary Ammonium Compounds/chemistry
10.
Chem Biol Interact ; 157-158: 199-203, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16263104

ABSTRACT

The use of exogenously administered cholinesterases (ChEs) as bioscavengers of highly toxic organophosphate (OP) nerve agents is now sufficiently well documented to make them a highly viable prophylactic treatment against this potential threat. Of the ChEs evaluated so far, human serum butyrylcholinesterase (HuBChE) is most suitable for human use. A dose of 200 mg (3 mg/kg) of HuBChE is envisioned as a prophylactic treatment in humans that can protect from an exposure of up to 2 x LD50 of soman. In addition to its use as a prophylactic for a variety of wartime scenarios, including covert actions, it also has potential use for first responders (civilians) reacting to terrorist nerve gas release. We recently, developed a procedure for the large-scale purification of HuBChE, which yielded approximately 6 g of highly purified enzyme from 120 kg of Cohn fraction IV-4. The enzyme had a specific activity of 700-750 U/mg and migrated as a single band on SDS-PAGE. To provide data for initiating an investigational new drug (IND) application for the use of this enzyme as a bioscavenger in humans, we established its pharmacokinetic properties, examined its safety in mice, and evaluated its shelf life at various temperatures. In mice administered various doses up to 90 mg/kg, enzyme activity reached peak levels in circulation at 10 and 24 h following i.p. and i.m. injections, respectively. The enzyme displayed a mean residence time (MRT) of 40-50 h, regardless of the route of administration or dose of injected enzyme. Mice were euthanized 2 weeks following enzyme administration and tissues were examined grossly or microscopically for possible toxic effects. Results suggest that HuBChE does not exhibit any toxicity in mice as measured by general observation, serum chemistry, hematology, gross or histologic tissue changes. The shelf life of this enzyme stored at 4, 25, 37, and 45 degrees C was determined in lyophilized form. The enzyme was found to be stable when stored in lyophilized form at -20, 4, 25, or 37 degrees C to date (2 years), as measured by specific activity and SDS polyacrylamide gel electrophoresis. The effect of storage on circulatory stability was determined by measuring MRT in mice; there was no change in the MRT of lyophilized enzyme stored at -20 degrees C to date (2 years). These results provide convincing data that HuBChE is a safe bioscavenger that can provide protection against all OP nerve agents. Efforts are now underway to prepare the required documentation for submission of an IND application to the United States Food and Drug Administration (USFDA).


Subject(s)
Butyrylcholinesterase/adverse effects , Butyrylcholinesterase/pharmacokinetics , Animals , Antidotes , Butyrylcholinesterase/administration & dosage , Enzyme Stability , Humans , Mice , Soman/antagonists & inhibitors , Soman/toxicity , Temperature
11.
Chem Biol Interact ; 157-158: 428-9, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16429577

ABSTRACT

Human serum butyrylcholinesterase (Hu BChE) has been demonstrated to be a highly effective detoxifying enzyme for counteracting the acute toxicity of organophosphorus (OP) nerve agents. In order to initiate an investigational new drug (IND) application for human use, the safety and pharmacokinetic properties of the enzyme were assessed in guinea pigs. Sixty milligrams per kilogram of Hu BChE was administered to guinea pigs by either i.p. or i.m. injection. Blood was drawn at various time points for up to 2 weeks following enzyme injection for the measurement of blood BChE activity. Hu BChE displayed a mean residence time of 110 h, regardless of the route of administration and the enzyme activity remained almost 10-fold above baseline level even after 2 weeks post enzyme injection. Fourteen days post Hu BChE administration, all animals were subjected to 20 panel serum chemistry, hematology, and complete gross/histopathology examination. Results showed no toxic effects as measured by general observation, serum chemistry, hematology, and gross and histological tissue changes. In conclusion, Hu BChE displays a long-lasting stability in the circulation of guinea pigs, and is devoid of any toxic side effects. These results provide convincing data for the safe and effective use of Hu BChE as a bioscavenger to protect humans against all OP nerve agents.


Subject(s)
Butyrylcholinesterase/adverse effects , Butyrylcholinesterase/pharmacokinetics , Animals , Butyrylcholinesterase/administration & dosage , Butyrylcholinesterase/blood , Guinea Pigs , Humans
12.
Life Sci ; 72(2): 125-34, 2002 Nov 29.
Article in English | MEDLINE | ID: mdl-12417246

ABSTRACT

Exposure to organophosphorus compounds (OPs), in the form of nerve agents and pesticides poses an ever increasing military and civilian threat. In recent years, attention has focused on the use of exogenously administered cholinesterases as an effective prophylactic treatment for protection against OPs. Clearly, a critical prerequisite for any potential bioscavenger is a prolonged circulatory residence time, which is influenced by the size of protein, the microheterogeneity of carbohydrate structures, and the induction (if any) of anti-enzyme antibodies following repeated injections of the enzyme. Previously, it was demonstrated that multiple injections of equine butyrylcholinesterase (BChE) into rabbits, rats, or rhesus monkeys, resulted in a mean residence time spanning several days, and variable immune responses. The present study sought to assess the pharmacokinetics and immunological consequences of administration of purified macaque BChE into macaques of the same species at a dose similar to that required for preventing OP toxicity. An i.v. injection of 7,000 U of homologous enzyme in monkeys demonstrated much longer mean residence times in plasma (MRT = 225 +/- 19 h) compared to those reported for heterologous Hu BChE (33.7 +/- 2.9 h). A smaller second injection of 3,000 U given four weeks later, attained predicted peak plasma levels of enzyme activity, but surprisingly, the MRT in the four macaques showed wide variation and ranged from 54 to 357 h. No antibody response was detected in macaques following either injection of enzyme. These results bode well for the potential use of human BChE as a detoxifying drug in humans.


Subject(s)
Butyrylcholinesterase/immunology , Butyrylcholinesterase/pharmacokinetics , Animals , Butyrylcholinesterase/adverse effects , Enzyme-Linked Immunosorbent Assay , Horses , Humans , Immunoglobulin G/immunology , Macaca mulatta , Organophosphate Poisoning , Organophosphorus Compounds/metabolism , Spectrophotometry, Ultraviolet
SELECTION OF CITATIONS
SEARCH DETAIL
...